Gimv’s medtech portfolio company JenaValve raises USD 26.5 million
JenaValve (www.jenavalve.com), today announced that it raised USD 26.5 million financing from an international investor syndicate including Gimv. This is one of the largest financing rounds for a medtech company in Europe.
JenaValve, with operations in Munich (GER), Leeds (UK) and Irvine, California (US), develops, manufactures and markets transcatheter aortic valve repair (TAVR) systems. The proceeds from the financing will be used to enable clinical studies and commercial development of innovative transcatheter aortic valve repair (TAVR) systems and strengthen the company’s position in this market.
Gimv was lead investor in the previous Series B financing round and confirms with this follow-on investment its belief in the further growth of the company.
For more information on this transaction we refer to the press release of JenaValve in attach.